Low high-density lipoprotein cholesterol: An important consideration in coronary heart disease risk assessment

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 2, 2008, Pages 175-181

  Majeed, Farhan ^a   Miller, Michael ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Coronary heart disease; Epidemiology; High density lipoprotein cholesterol

Indexed keywords

GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TORCETRAPIB; TRIACYLGLYCEROL; CARDIOTONIC AGENT;

AEROBIC EXERCISE; ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; DYSPEPSIA; FIBRINOLYSIS; FLUSHING; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIVER TOXICITY; MORTALITY; PREDICTOR VARIABLE; PREVALENCE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; BIOLOGICAL MODEL; BLOOD; CORONARY ARTERY DISEASE; GENETICS; PREDICTION AND FORECASTING;

CARDIOTONIC AGENTS; CHOLESTEROL, HDL; CORONARY DISEASE; HUMANS; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 42449130136     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3282f79b0b     Document Type: Review

References (74)

1. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
2. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1:16-19.
3. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62:707-714.
4. Assmann G, Cullen P, Schulte H, The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19:A2-A11.
5. Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004; 109 (23 Suppl 1):III8-III14.
6. Heart disease and stroke statistics 2005 update. Dallas, Texas: American Heart Association; 2005.
7. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
8. Mosca L, Grundy SM, Judelson D, et al. Guide to preventive cardiology for women: AHA/ACC Scientific Statement Consensus panel statement. Circulation 1999; 99:2480-2484.
9. Genest JJ, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025-2033.
10. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996; 124:S1-S9.
11. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359.
12. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93:136-141.
13. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, et al. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 2004; 114:1343-1353.
14. Miller M, Rhyne J, Hamlette S, et al. Genetics of HDL regulation in humans. Curr Opin Lipidol 2003; 14:273-279.
15. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005; 36:232-240.
16. Ginsberg H, Grabowski GA, Gibson JC, et al. Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease. Clin Genet 1984; 26:109-116.
17. Keddad K, Razavian SM, Baussan C, et al. Blood lipids and rheological modifications in glycogen storage disease. Clin Biochem 1996; 29:73-78.
18. Viana MB, Giugliani R, Leite VH, et al. Very low levels of high density lipoprotein cholesterol in four sibs of a family with nonneuropathic Niemann-Pick disease and sea-blue histiocytosis. J Med Genet 1990; 28:499-504.
19. McCall MR, van den Berg JJ, Kuypers FA, et al. Modification of LCAT activity and HDL structure: new links between cigarette smoke and coronary heart disease risk. Arterioscler Thromb 1994; 14:248-253.
20. Sacks FM, Katan M. Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. Am J Med 2002; 113:13S-24S.
21. Grimm RH Jr. Antihypertensive therapy: taking lipids into consideration. Am Heart J 1991; 122:910-918.
22. Fahraeus L, Larsson-Cohn U, Ljungberg S, et al. Plasma lipoproteins during and after danazol treatment. Acta Obstet Gynecol Scand Suppl 1984; 123:133-135.
23. Cantwell JD. Serum lipid levels in a major league baseball team. Am J Cardiol 2002; 90:1395-1397.
24. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007; 298:786-798. Excellent mechanistic review of the potential antiatherothrombotic role that HDL may play in CHD and new therapeutic targets to treat low HDL-C.
25. Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000; 101:2510-2517.
26. Xia P, Vadas MA, Rye KA, et al. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway: a possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999; 274:33143-33147.
27. Nofer JR, Walter M, Kehrel B, et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 1998; 18:861-869.
28. Li XP, Zhao SP, Zhang XY, et al. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol 2000; 73:231-236.
29. Vinals M, Martinez-Gonzalez J, Badimon L. Regulatory effects of HDL on smooth muscle cell prostacyclin release. Arterioscler Thromb Vasc Biol 1999; 19:2405-2411.
30. Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 2001; 276:34480-34485.
31. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62:707-714.
32. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79:8-15.
33. Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999; 99:736-743.
34. Campeau L, Hunninghake DB, Knatterud GL, et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. Circulation 1999; 99:3241-3247.
35. Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357:1301-1310. Post hoc analysis that showed increased residual risk of CHD events in the presence of low HDL-C.
36. Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid management. Am J Cardiol 2001; 87:2B-7B.
37. Williams PT. The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. Metabolism 2004; 53:700-709.
38. Miller M. Raising an isolated low HDL-C level: why, how, and when? Cleve Clin J Med 2003; 70:553-560.
39. Roberts CK, Ng C, Hama S, et al. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol 2006; 101:1727-1732. Small study in obese men demonstrating that weight loss induced by low fat intake and exercise improved HDL functionality by converting HDL from proinflammatory to anti-inflammatory particles.
40. Wilund KR, Ferrell RE, Phares DA, et al. Changes in high-density lipoprotein-cholesterol subfractions with exercise training may be dependent on cholesteryl ester transfer protein (CETP) genotype. Metabolism 2002; 51:774-778.
41. King AC, Haskell WL, Young DR, et al. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation 1995; 91:2596-2604.
42. Jafari M, Leaf DA, Macrae H, et al. The effects of physical exercise on plasma prebeta-1 high-density lipoprotein. Metabolism 2003; 52:437-442.
43. Couillard C, Despres JP, Lamarche B, et al. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001; 21:1226-1232.
44. Weisweiler P. Plasma lipoproteins and lipase and lecithin : cholesterol acyltransferase activities in obese subjects before and after weight reduction. J Clin Endocrinol Metab 1987; 65:969-973.
45. Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999; 319:1523-1528.
46. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993; 329:1829-1834.
47. Van Der Gaag MS, Van Tol A, Vermunt SH, et al. Alcohol consumption stimulates early steps in reverse cholesterol transport. J Lipid Res 2001; 42:2077-2083.
48. Ellison RC, Zhang Y, Qureshi MM, et al. Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J 2004; 147:529-535.
49. Imamura H, Teshima K, Miyamoto N, et al. Cigarette smoking, high-density lipoprotein cholesterol subfractions, and lecithin: cholesterol acyltransferase in young women. Metabolism 2002; 51:1313-1316.
50. Mero N, Van Tol A, Scheek LM, et al. Decreased postprandial high density lipoprotein cholesterol and apolipoproteins A-I and E in normolipidemic smoking men: relations with lipid transfer proteins and LCAT activities. J Lipid Res 1998; 39:1493-1502.
51. Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 2003; 37:283-290.
52. Nicholls SJ, Lundman P, Harmer JA, et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol 2006; 48:715-720.
53. Mensink RP, Zock PL, Kester AD, et al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003; 77:1146-1155.
54. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985; 312:1205-1209.
55. Slyper A, Jurva J, Pleuss J, et al. Influence of glycemic load on HDL cholesterol in youth. Am J Clin Nutr 2005; 81:376-379.
56. Miller M. Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc 2003; 78:735-742.
57. Kuvin JT, Ramet ME, Patel AR, et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002; 144:165-172.
58. Alderman JD, Pasternak RC, Sacks FM, et al. Effect of a modified, well tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol 1989; 64:725-729.
59. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-381.
60. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255.
61. Benyó Z, Gille A, Bennett CL, et al. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol 2006; 70:1844-1849. First demonstration that the epidermal Langerhans cells play a pivotal role that leads to nicotinic acid mediated flushing and vasodilation. The process originates with niacin binding to its receptor, resulting in production of prostaglandin D2 by these specialized cells.
62. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 2006; 103:6682-6687. Demonstration in a mouse model that binding of prostaglandin D2 to its receptor (DP1) plays an important role in niacin-induced flushing. In human volunteers, pretreatment with the DP1 antagonist MK-0524 reduced symptoms of flushing and vasodilation associated with nicotinic acid administration.
63. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418.
64. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245.
65. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285:1585-1591.
66. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with feno-fibrate+statin versus gemfibrozil+any statin. Am J Cardiol 2005; 95:120-122.
67. Deakin S, Leviev I, Guernier S, et al. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003; 23:2083-2089.
68. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
69. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297:499-508. Review of statin-based trials suggesting that regression of coronary artery disease is more likely attainable when both LDL-C is reduced and HDL-C is increased by more than 7.5%.
70. Barter PJ, Caulfield M, Eriksson M, et al., ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122. Results of the prematurely terminated ILLUMINATE study demonstrating increased mortality in stable coronary artery disease patients assigned to the combination of the CETP inhibitor, torcetrapib and atorovastatin compared with atorvastatin alone. Increased mortality appears to reflect an off-target effect of the agent (stimulation of the rennin-angiotensin-aldosterone pathway) rather than CETP inhibition per se.
71. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007; 27:257-260. Discussion of torcetrapib's potential pitfalls in ILLUMINATE after the study was prematurely terminated before the data were published.
72. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-2300.
73. Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 2006; 3:540-547.
74. Haffner SM, American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27:S168-S171.